Frontiers in Endocrinology · Nov 18, 2026

Differential Associations of Distinct Exposure Dimensions of Estimated Glucose Disposal Rate With Incident Cardiovascular Disease in Early-Stage Cardiovascular-Kidney-Metabolic Syndrome: A Prospective Cohort Study Based on CHARLS

By Zhiqing Fu, Li An, Wei Zhang et al.

Background Stages 0–3 of cardiovascular-kidney-metabolic (CKM) syndrome are a critical window to prevent overt cardiovascular disease (CVD). Insulin resistance (IR) drives CKM pathogenesis. However, the association strengths and predictive performance of baseline, cumulative, and cluster-based estimated glucose disposal rate (eGDR)—have not been directly compared in this preclinical population. Methods We enrolled 3,182 participants with CKM stages 0–3 from CHARLS. K-means clustering grouped participants by eGDR levels across two measurements. Cox regression, restricted cubic spline (RCS) curves, and Kaplan–Meier curves evaluated associations between eGDR dimensions and incident CVD. Receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis compared predictive performance. Stratified analyses were performed by CKM stages. Results Over a median follow-up of 60 months, 570 (17.9%) CVD events occurred. All three eGDR metrics were inversely associated with CVD risk. Compared with the lowest tertile, the highest tertile yielded HRs of 0.52 (95% CI: 0.42–0.64) and 0.45 (95% CI: 0.36–0.56) for baseline and cumulative eGDR, respectively; each 1-SD increment corresponded to 25% and 29% risk reductions. The persistently high eGDR cluster yielded an HR of 0.46 (95% CI: 0.38–0.56) versus the persistently low cluster. RCS analyses showed linear dose–response relationships. The AUC values for baseline, cumulative, and eGDR clusters were 0.639, 0.645, and 0.643, respectively, with no significant differences. Adding cumulative eGDR or eGDR cluster to the basic model yielded statistically significant but modest improvements in reclassification (NRI: 0.183 and 0.230; P < 0.001) and discrimination (IDI: 0.0067 and 0.0053; P < 0.001); baseline eGDR improved IDI (0.0025, P = 0.036) but not NRI. In stage-specific analyses, cumulative eGDR was significantly associated with CVD risk in both early and clinical stages, whereas baseline eGDR was significant only in stages 2–3. Subgroup and sensitivity analyses confirmed robustness. Conclusions All three eGDR dimensions were inversely associated with CVD across CKM stages 0–3, with comparable predictive performance. Cumulative eGDR showed numerically stronger associations, though differences were not statistically significant. Notably, cumulative eGDR remained significant in early stages (0–1) where baseline eGDR was not, suggesting it may be a useful complement for early risk stratification.

The paperJournal siteBiomarkers

AgingResearch.News